Karolinska Development's portfolio company Aprea Therapeutics receives FDA fast track designation for eprenetapopt in AML

Karolinska Development

30 November 2020 - Karolinska Development announces today that the U.S. FDA has granted fast track designation for eprenetapopt in the treatment of patients with TP53 mutant acute myeloid leukaemia. 

The company previously received breakthrough therapy, orphan drug and fast track designations for eprenetapopt in the treatment of patients with TP53 mutant myelodysplastic syndromes.

Read Karolinska Development press release

Michael Wonder

Posted by:

Michael Wonder

Posted in:

Cancer , Medicine , US , Fast track